SCHEMBL1248433

SCHEMBL1248433

Cc1nc2cc(NC(=O)c3ccc4nc(-c5c(C)cc(OS(C)(=O)=O)cc5C)[nH]c4c3)ccc2s1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 8/20 0.60
TRPV1 Q8NER1 1/20 0.49
HDAC3 O15379 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
HDAC9 Q9UKV0 1/20 0.47
RAB9A P51151 7/20 0.46
NPC1 O15118 6/20 0.46
CYP3A4 P08684 1/20 0.46
LMNA P02545 1/20 0.45
POLB P06746 1/20 0.45
MAPT P10636 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
CASP3 P42574 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
RPS6KA2 Q15349 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1251630 0.91 DGAT1 (0.58) DGAT1TRPV1HDAC3HDAC7HDAC6
SCHEMBL1251238 0.90 DGAT1 (0.56) DGAT1TRPV1HDAC3HDAC7HDAC6
SCHEMBL1248700 0.87 DGAT1 (0.79) DGAT1HDAC3HDAC7HDAC6HDAC9
SCHEMBL1251610 0.86 DGAT1 (0.77) DGAT1TRPV1HDAC3HDAC7HDAC6
SCHEMBL1250286 0.85 DGAT1 (0.64) DGAT1TRPV1HDAC3HDAC7HDAC6
SCHEMBL1251408 0.85 DGAT1 (0.66) DGAT1TRPV1HDAC3HDAC7HDAC6
SCHEMBL1250424 0.85 DGAT1 (0.65) DGAT1TRPV1HDAC3HDAC7HDAC6
SCHEMBL1250680 0.84 DGAT1 (0.64) DGAT1TRPV1HDAC3HDAC7HDAC6
SCHEMBL1250693 0.81 DGAT1 (0.60) DGAT1TRPV1HDAC3HDAC7HDAC6
SCHEMBL1250949 0.81 DGAT1 (0.69) DGAT1TRPV1RAB9ANPC1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2074089-B1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2013-09-18 EP disclosed
US-8222248-B2 Organic compounds NOVARTIS AG (CH) 2012-07-17 US disclosed
US-8222248-B2 Organic compounds NOVARTIS AG (CH) 2012-07-17 US disclosed
US-20110046133-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2011-02-24 US disclosed
US-20110046133-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2011-02-24 US disclosed
US-20100016387-A1 METHOD OF TREATMENT BOSE AVIRUP 2010-01-21 US disclosed
WO-2009112445-A1 METHOD OF INCREASING CELLULAR PHOSPHATIDYL CHOLINE BY DGAT1 INHIBITION NOVARTIS AG (CH) 2009-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046133-A1 ORGANIC COMPOUNDS DGAT1, DGAT2, SOAT1 DGAT1 1/4885TRPV1 1707/4885HDAC3 882/4885
US-20100016387-A1 METHOD OF TREATMENT DGAT1, DGAT2, DGKA DGAT1 1/4885TRPV1 3222/4885HDAC3 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.